MX2015002900A - Derivados de pirazol carboxamida como moduladores de los receptores asociados con las aminas traza (taar) para uso en el tratamiento de varios trastornos, tales como depresion, diabetes y enfermedades de parkinson. - Google Patents
Derivados de pirazol carboxamida como moduladores de los receptores asociados con las aminas traza (taar) para uso en el tratamiento de varios trastornos, tales como depresion, diabetes y enfermedades de parkinson.Info
- Publication number
- MX2015002900A MX2015002900A MX2015002900A MX2015002900A MX2015002900A MX 2015002900 A MX2015002900 A MX 2015002900A MX 2015002900 A MX2015002900 A MX 2015002900A MX 2015002900 A MX2015002900 A MX 2015002900A MX 2015002900 A MX2015002900 A MX 2015002900A
- Authority
- MX
- Mexico
- Prior art keywords
- lower alkyl
- halogen
- substituted
- disorders
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula (I) en la que R1 es fenilo opcionalmente sustituido por halógeno, alquilo inferior, cicloalquilo inferior, alcoxi inferior, ciano, alquilo inferior sustituido por halógeno, alquilo inferior sustituido por hidroxi, alcoxi inferior sustituido por halógeno o alcoxi inferior sustituido por hidroxi; o es piridin-2-, -3- o -4-ilo opcionalmente sustituido por halógeno, alquilo inferior, cicloalquilo inferior, ciano, alquilo inferior sustituido por halógeno, alquilo inferior sustituido por hidroxi, alcoxi inferior, alcoxi inferior sustituido por halógeno o alcoxi inferior sustituido por hidroxilo; o es pirimidin-2-, -4- o -5-ilo opcionalmente sustituido por halógeno, alquilo inferior, cicloalquilo inferior, alquilo inferior sustituido por hidroxi o alquilo inferior sustituido por halógeno; o es pirazin-2-ilo opcionalmente sustituido por halógeno, alquilo inferior, cicloalquilo inferior, alquilo inferior sustituido por halógeno, alquilo inferior sustituido por hidroxi o ciano; o es 2,2-difluorbenzo[d] [1,3]dioxol-5-ilo, o es tiazolilo opcionalmente sustituido por alquilo inferior sustituido por halógeno; R2 es hidrógeno o alquilo inferior; R3 es hidrógeno, amino o alquilo inferior; Z es un enlace, - CH2- u -O-; o a una sal de adición de ácido farmacéuticamente apropiada de los mismos. Ahora se ha encontrado que los compuestos de las fórmulas I tienen una buena afinidad con los receptores asociados con las aminas traza (TAAR), en especial con el TAAR1. Los compuestos pueden utilizarse para el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, trastorno de hiperactividad con déficit de atención (ADHD), los trastornos relacionados con el estrés, trastornos psicóticos, esquizofrenia, enfermedades neurológicas, enfermedad de Parkinson, trastornos neurodegenerativos, enfermedad de Alzheimer, epilepsia, migraña, hipertensión, abuso de sustancias, trastornos metabólicos, trastornos de ingestión de comida, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consumo y asimilación de energía, trastornos y malfunción de la homeostasis de la temperatura corporal, trastornos del sueño y del ritmo circadiano y trastornos cardiovasculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12184360 | 2012-09-14 | ||
PCT/EP2013/068769 WO2014041007A1 (en) | 2012-09-14 | 2013-09-11 | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015002900A true MX2015002900A (es) | 2015-06-03 |
MX363362B MX363362B (es) | 2019-03-21 |
Family
ID=47044779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015002900A MX363362B (es) | 2012-09-14 | 2013-09-11 | Derivados de pirazol carboxamida como moduladores de los receptores asociados con las aminas traza (taar) para uso en el tratamiento de varios trastornos, tales como depresión, diabetes y enfermedades de parkinson. |
Country Status (35)
Country | Link |
---|---|
US (1) | US9487501B2 (es) |
EP (1) | EP2895477B1 (es) |
JP (2) | JP2015531782A (es) |
KR (1) | KR101706486B1 (es) |
CN (2) | CN107903251A (es) |
AR (1) | AR092537A1 (es) |
AU (1) | AU2013314388B2 (es) |
BR (1) | BR112015004511B1 (es) |
CA (1) | CA2882821C (es) |
CL (1) | CL2015000580A1 (es) |
CR (1) | CR20150087A (es) |
DK (1) | DK2895477T3 (es) |
EA (1) | EA026062B1 (es) |
ES (1) | ES2654653T3 (es) |
HK (2) | HK1206720A1 (es) |
HR (1) | HRP20171981T1 (es) |
HU (1) | HUE037689T2 (es) |
IL (1) | IL237332B (es) |
LT (1) | LT2895477T (es) |
MA (1) | MA37944B2 (es) |
MX (1) | MX363362B (es) |
MY (1) | MY178667A (es) |
NO (1) | NO2895477T3 (es) |
NZ (1) | NZ705154A (es) |
PE (1) | PE20150735A1 (es) |
PH (1) | PH12015500489B1 (es) |
PL (1) | PL2895477T3 (es) |
PT (1) | PT2895477T (es) |
RS (1) | RS56747B1 (es) |
SG (1) | SG11201501958QA (es) |
SI (1) | SI2895477T1 (es) |
TW (1) | TWI610926B (es) |
UA (1) | UA113776C2 (es) |
WO (1) | WO2014041007A1 (es) |
ZA (1) | ZA201501126B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106715395B (zh) * | 2014-07-30 | 2020-05-12 | 豪夫迈·罗氏有限公司 | 作为taar调节剂的6-氨基-5,6,7,8-四氢萘-2-基或3-氨基色满-7-基衍生物 |
SG10201913878YA (en) | 2016-03-17 | 2020-03-30 | Hoffmann La Roche | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
JP7191828B2 (ja) * | 2016-12-15 | 2022-12-19 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | がん治療のための組成物および方法 |
SG11202110401WA (en) | 2019-04-09 | 2021-10-28 | Hoffmann La Roche | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
WO2022262855A1 (zh) * | 2021-06-18 | 2022-12-22 | 上海拓界生物医药科技有限公司 | 一种malt1抑制剂及其制备方法和用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
CN101616902B (zh) | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
TW201236685A (en) * | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
-
2013
- 2013-09-11 HU HUE13759754A patent/HUE037689T2/hu unknown
- 2013-09-11 SI SI201330900T patent/SI2895477T1/en unknown
- 2013-09-11 RS RS20171358A patent/RS56747B1/sr unknown
- 2013-09-11 ES ES13759754.8T patent/ES2654653T3/es active Active
- 2013-09-11 CN CN201711272710.XA patent/CN107903251A/zh active Pending
- 2013-09-11 NO NO13759754A patent/NO2895477T3/no unknown
- 2013-09-11 EA EA201590454A patent/EA026062B1/ru not_active IP Right Cessation
- 2013-09-11 PE PE2015000364A patent/PE20150735A1/es active IP Right Grant
- 2013-09-11 MY MYPI2015000641A patent/MY178667A/en unknown
- 2013-09-11 CN CN201380047584.1A patent/CN104619700A/zh active Pending
- 2013-09-11 AU AU2013314388A patent/AU2013314388B2/en active Active
- 2013-09-11 PL PL13759754T patent/PL2895477T3/pl unknown
- 2013-09-11 DK DK13759754.8T patent/DK2895477T3/en active
- 2013-09-11 CA CA2882821A patent/CA2882821C/en active Active
- 2013-09-11 NZ NZ705154A patent/NZ705154A/en unknown
- 2013-09-11 WO PCT/EP2013/068769 patent/WO2014041007A1/en active Application Filing
- 2013-09-11 BR BR112015004511-1A patent/BR112015004511B1/pt active IP Right Grant
- 2013-09-11 UA UAA201503288A patent/UA113776C2/uk unknown
- 2013-09-11 EP EP13759754.8A patent/EP2895477B1/en active Active
- 2013-09-11 PT PT137597548T patent/PT2895477T/pt unknown
- 2013-09-11 KR KR1020157009118A patent/KR101706486B1/ko active IP Right Grant
- 2013-09-11 JP JP2015531543A patent/JP2015531782A/ja active Pending
- 2013-09-11 SG SG11201501958QA patent/SG11201501958QA/en unknown
- 2013-09-11 MX MX2015002900A patent/MX363362B/es unknown
- 2013-09-11 MA MA37944A patent/MA37944B2/fr unknown
- 2013-09-11 LT LTEP13759754.8T patent/LT2895477T/lt unknown
- 2013-09-12 AR ARP130103258A patent/AR092537A1/es not_active Application Discontinuation
- 2013-09-13 TW TW102133263A patent/TWI610926B/zh active
-
2015
- 2015-02-18 ZA ZA2015/01126A patent/ZA201501126B/en unknown
- 2015-02-19 IL IL237332A patent/IL237332B/en active IP Right Grant
- 2015-02-20 CR CR20150087A patent/CR20150087A/es unknown
- 2015-03-06 PH PH12015500489A patent/PH12015500489B1/en unknown
- 2015-03-09 CL CL2015000580A patent/CL2015000580A1/es unknown
- 2015-03-13 US US14/656,853 patent/US9487501B2/en active Active
- 2015-07-27 HK HK15107153.1A patent/HK1206720A1/xx unknown
- 2015-07-27 HK HK18112341.1A patent/HK1252981A1/zh unknown
-
2017
- 2017-02-22 JP JP2017031116A patent/JP6529998B2/ja active Active
- 2017-12-19 HR HRP20171981TT patent/HRP20171981T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG195156A1 (en) | Pyrazole derivatives | |
MX351918B (es) | Derivados heterociclicos de amina. | |
PH12015500489B1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease | |
MY176030A (en) | Substituted benzamide derivatives | |
MX2009003887A (es) | Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina. | |
UA98951C2 (ru) | 2-аминооксазолины и лекарственное средство, которое их содержит | |
TW200833685A (en) | Aminomethyl-4-imidazoles | |
MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
MX354410B (es) | Derivados de benzamida sustituida. | |
ECSP11010782A (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
MX2012005363A (es) | Derivados de oxazolina para el tratamiento de trastornos del sistema nervioso central (snc). | |
MX361761B (es) | Derivados de triazol carboxamida. | |
TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
MX2009006215A (es) | 4-imidazolinas como ligandos de aminas trazas. | |
MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
MX2016013412A (es) | Derivados de morfolina-piridina. | |
MX349738B (es) | Derivados de dihidrooxazol-2-amina. | |
MX2009005047A (es) | 4-imidazoles sustituidos. | |
MX2016012624A (es) | Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como modularores de los receptores asociados a la amina de trazas 1 (taar1). | |
TH156898A (th) | อนุพันธ์ไพราโซลคาร์บอกซาไมด์ในฐานะ taar โมดูเลเตอร์สำหรับใช้ในการรักษา ความผิดปกติหลายชนิดอย่างเช่นภาวะซึมเศร้า, เบาหวาน และโรคพาร์กินสัน | |
MX2016016190A (es) | Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central. |